Press Releases

    • SEP 10 2018

    NCI and Musella Foundation Award Grants for ONC201 Trials in Adult and Pediatric Brain Tumors

    Philadelphia, PA (September 10, 2018) – Oncoceutics, Inc. announced the receipt of a Small Business Innovation Research (SBIR) Phase IIB Bridge Award from the National Cancer Institute (NCI).  The NCI SBIR Bridge Award will allow Oncoceutics to expand and accelerate its clinical trials evaluating ONC201 in patients with a specific type of lethal brain cancer

    • AUG 06 2018

    Clinical Cancer Research Article Describes Opportunity to Use Imipridones for Brain Tumors

    Philadelphia, PA (July 31, 2018) – Oncoceutics, Inc. announced the publication of a scientific research article in the journal Clinical Cancer Research that demonstrates utility for the company’s imipridone portfolio of compounds in neuro-oncology. Oncoceutics developed this portfolio of chemical compounds that target G protein-coupled receptors (GPCRs) using the unique core chemical structure of the

    • MAY 29 2018

    Oncoceutics Abstracts at ASCO Highlight Efficacy of ONC201 in High-Grade Gliomas

    Philadelphia, PA (May 29, 2018) – Oncoceutics, Inc. announced that two abstracts will be presented at the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO) that will highlight clinical success of the company’s lead compound in treating high-grade gliomas (HGG), including those that harbor the H3 K27M mutation. The first abstract, entitled

    • MAY 17 2018

    Oncoceutics Announces Support for Legislation Increasing Awareness for DIPG

    Philadelphia, PA (May 16, 2018) – Oncoceutics, Inc. announced today its support for legislation that will increase awareness for diffuse intrinsic pontine glioma (DIPG), the most devastating type of brain cancer in children. Oncoceutics supports the efforts of the Jack’s Angels Foundation and Rep. Stephen Knight (CA) to pass H.Res.69 to designate May 17th as